The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Home Explore BioSpectrum Asia November 2022
View in Fullscreen

Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,
according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.

Like this book? You can publish your book online for free in a few minutes!
Download PDF
Share

Related Publications

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2022-10-28 09:12:42

BioSpectrum Asia November 2022

Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,
according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.

Keywords: Diabetes,Pharma industry

ASIA JOBS

The Premier Source for latest jobs and trends in
Pharma, healthcare & biotechnology & research

We connect millions of readers to new trends &
opportunities worldwide.

Trusted by the Business of Biotech & Health Sciences, University
Professors, Companies and Other Research Organizations

For Job Seekers For Job Employer

Search job by location Post Unlimited Jobs
Create multiple job alerts Activate & deactivate jobs
Customize job search according Candidate Search
to industry, Career type Download candidates resume
Receive industry updates
Expert’s thoughts from leaders

Please visit: https://www.biospectrumjobs.com
For more information Email us at: [email protected]


Click to View FlipBook Version